Fennec Pharmaceuticals
FENC
78 hedge funds and large institutions have $113M invested in Fennec Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 6 closing their positions.
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
38% more capital invested
Capital invested by funds: $81.6M → $113M (+$31.3M)
15% more funds holding
Funds holding: 68 → 78 (+10)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
0.74% more ownership
Funds ownership: 48.53% → 49.27% (+0.74%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$1.8M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$625K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$538K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$320K |
| 5 |
Jane Street
New York
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HFA
Harbert Fund Advisors
Birmingham,
Alabama
|
-$1.23M |
| 2 |
DCM
DG Capital Management
New York
|
-$513K |
| 3 |
GJL
Gendell Jeffrey L
|
-$380K |
| 4 |
Morgan Stanley
New York
|
-$290K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$263K |
FENC Hedge Fund Activity: Q2 2025 in Review
78 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2025, worth a combined $113M — up 38% from $81.6M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new FENC positions and 6 closed out — a net gain of 10 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was Rosalind Advisors, adding an estimated $1.8M. The largest seller was Harbert Fund Advisors, cutting an estimated $1.23M.
- 78 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2025, up from 68 in Q1 2025.
- Funds reported $113M of Fennec Pharmaceuticals stock for Q2 2025, up 38% quarter-over-quarter.
- 16 funds opened new Fennec Pharmaceuticals positions in Q2 2025 and 6 closed out, a net change of +10 holders.
- The largest Fennec Pharmaceuticals buyer in Q2 2025 was Rosalind Advisors, an estimated $1.8M added.
- The largest Fennec Pharmaceuticals seller in Q2 2025 was Harbert Fund Advisors, an estimated $1.23M sold.
Based on aggregated 13F filings for Q2 2025.